# A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

> **NCT05089409** · PHASE1 · COMPLETED · sponsor: **AmtixBio Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Onychomycosis

## Interventions

- **DRUG:** ATB1651, 2 mg/mL
- **DRUG:** ATB1651, 5 mg/mL
- **DRUG:** ATB1651, 10 mg/mL
- **DRUG:** ATB1651, 20 mg/mL
- **DRUG:** ATB1651, 30 mg/mL
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05089409
- **Lead sponsor:** AmtixBio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-04
- **Primary completion:** 2023-06-03
- **Final completion:** 2023-09-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089409, "A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05089409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*